Alternatives to Antibiotics

by Wayne Persky

RSS Feed

The first true antibiotic, penicillin, was discovered in 1928. But the prestige of that lifesaving discovery was slightly tarnished when the first case of penicillin resistance appeared in 1947. During the decade between 1950 and 1960, approximately half of the antibiotics in use today were discovered, earning this decade the title of the "Golden age of antibiotic discovery".

Antibiotic resistance continues to increase.

The growing problem of antibiotic resistance is a constant reminder that we need to find alternatives to antibiotics. And now, the recent research discovery that antibiotics increase the risk of developing IBD, adds another level of urgency to the dilemma.

Precious few alternatives to antibiotics are currently available.

Currently, there are very few practical alternatives to antibiotics, but there are a number of promising therapies under development that may prove to provide effective results to complete with current antibiotics, at some point in the near future. Here's a brief look at some of these possible future (in most cases) options. And please note that there are never any guarantees regarding developmental research, so the estimated availability times are little more than best guesses, subject to change, depending on the outcomes of laboratory procedures, treatment trials, FDA discretionary actions, and other influences.

1. Phage Therapy — Phage therapy uses bacteriophages, which are viruses that specifically infect and kill bacteria. Bacteriophages target specific bacterial strains without affecting beneficial bacteria or the body’s own cells, unlike broad-spectrum antibiotics. This technique has been researched for treating antibiotic-resistant infections such as MRSA (methicillin-resistant Staphylococcus aureus) and Pseudomonas infections. Phage therapy is highly targeted, reducing the risk of collateral damage to the microbiome and lessening the development of resistance.
​
Phage therapy is in experimental stages in most of the world, with early clinical trials underway, especially in the U.S. and Europe. Some compassionate use cases exist for multidrug-resistant infections, but widespread regulatory approval is still pending. Regulatory approval, standardization of treatment, and creating phage banks for various bacterial infections are hurdles. Estimated Availability is 5 to 10 years.

What will it cost?

Considering the variability, the total cost of phage therapy (including medication, customization, and treatment) could range anywhere from $8,000 to $40,000 or more. The cost is likely to be higher in countries where phage therapy is not widely available or is considered experimental, requiring patients to travel to specialized clinics.

2. Antimicrobial Peptides (AMPs) — Antimicrobial peptides are small proteins produced by the immune system that can kill bacteria, viruses, fungi, and even cancer cells. AMPs disrupt the bacterial cell membranes, leading to cell death. They have broad-spectrum activity and are less likely to lead to resistance. AMPs are being developed to treat infections ranging from skin wounds to pneumonia and bloodstream infections. They have rapid bacterial killing activity and a lower likelihood of resistance.​

AMPs are in early stages of research and clinical trials. While they show promise, issues related to stability, toxicity, and effectiveness in humans still need to be addressed. Development of stable, non-toxic formulations suitable for systemic use and regulatory hurdles are the main challenges. Because they enhance cell growth and tissue repair, they're currently used in clinical treatment of pathogen infection, wound healing and cancer. Estimated Availability is 10 to 15 years.

What will it cost?

​Considering the cost of medication, customization, and clinical treatment, the total for antimicrobial peptide treatments is likely to range between $12,000 and $50,000 or more, depending on the specific AMP used, the complexity of the infection being treated, and the region where the treatment is administered.

3. Probiotics — Probiotics are live beneficial bacteria that can promote a healthy gut microbiome by competing with pathogenic bacteria. By producing antimicrobial substances, and supporting the immune system, probiotics can prevent and treat infections. Probiotics have been used to prevent infections like **Clostridioides difficile** (C. diff) and to reduce the risk of respiratory and urinary tract infections, and they can support gut health without disrupting the beneficial microbiome, making them a potential alternative to antibiotics for preventing infections.
​
Probiotics are already widely available as dietary supplements and are increasingly being used for gut health and adjunctive therapy in healthcare systems. Ensuring standardized and clinically effective strains for specific medical purposes remains an area of active research, but they are already part of healthcare treatments, particularly for gastrointestinal issues.

What will it cost?

• General Use (OTC or Clinical-Grade Probiotics) — $240 - $2,400 per year depending on whether OTC or clinical-grade probiotics are used.
• More Intensive Medical Use (for example, severe infections or gastrointestinal conditions): $1,500 - $5,000 or more for treatments that involve hospital care, monitoring, or the use of advanced probiotic therapies.​

4. Prebiotics— Prebiotics are non-digestible fibers that serve as food for beneficial bacteria in the gut. By feeding the beneficial bacteria, prebiotics can help maintain a balanced gut microbiome, which can prevent harmful bacteria from overgrowing. Prebiotics are used to improve digestive health and may reduce the risk of gastrointestinal infections, and they support long-term gut health, and may help prevent infections naturally without the need for antibiotics.
​
Prebiotics are available in food and supplements. Their role as part of gut health and adjunctive therapy is being explored further, but they are widely used already. Like probiotics, the challenge is identifying specific prebiotics that target particular gut bacteria for tailored therapeutic effects.

What will it cost?

• General Use (OTC Prebiotics or Food-Based Prebiotics): $120 - $480 per year for OTC prebiotics or slightly more if using prebiotic-enriched foods.
• Clinical-Grade or Specialized Prebiotics: $360 - $1,200 per year for more targeted, higher-grade products.
• Combination Synbiotic Treatments: $600 - $1,800 per year if using both prebiotics and probiotics in a single supplement.
• Specialized Medical Use: $500 - $3,000 if prebiotics are part of a broader clinical treatment involving medical supervision and testing.

​5. Herbal and Plant-Based Antimicrobials — Some herbs and plant-based substances have antimicrobial properties and have been used traditionally to treat infections. For example, garlic has broad-spectrum antimicrobial activity, and echinacea is believed to stimulate the immune system and may help in reducing the severity of infections. Cranberry is used primarily to prevent urinary tract infections. Tea tree oil is used topically for bacterial and fungal infections. These natural substances often have fewer side effects than antibiotics and may help in mild to moderate infections.

Some plant-based antimicrobials (for example, tea tree oil, and garlic extract) are already used in alternative medicine and supplements. More rigorous research is ongoing to establish their effectiveness and safety for clinical use. Lack of standardization and clinical trials to prove efficacy and safety are major obstacles. Widespread medical use will require clinical validation. Estimated Availability is 5 to 10 years (for medical-grade applications).

What will it cost?

• General Use (OTC Herbal Supplements): $120 - $600 per year for regular use of common herbal antimicrobials.
• Clinical-Grade or Specialized Herbal Antimicrobials: $360 - $1,200 per year for higher-quality products used in a clinical setting.
• Combination or Proprietary Herbal Formulas: $600 - $1,800 per year for combination treatments targeting specific infections.
• Consultations and Treatment Protocols for Chronic Conditions: $1,000 - $5,000 per year if herbal antimicrobials are part of a more comprehensive protocol, especially for chronic or difficult-to-treat conditions.

​6. Vaccines — Vaccines prevent infections by stimulating the immune system to recognize and attack specific pathogens. By introducing a weakened or inactive form of a pathogen, vaccines "train" the immune system to respond to future infections. Vaccines are a preventive measure against bacterial infections like pneumococcal pneumonia, tuberculosis, and bacterial meningitis, as well as viral infections like the flu and COVID-19, and they can prevent infections from occurring in the first place, thereby reducing the need for antibiotics.

Vaccines are already widely available and an essential part of preventive healthcare. Research into vaccines against multidrug-resistant bacteria is ongoing, and such vaccines may be available in the next 5 to 10 years. Vaccine development for specific drug-resistant bacteria is complex, but current vaccines are integral to modern medicine.

What will it cost?

• Routine Vaccines (Flu, Tetanus, Hepatitis, etc.): $0 - $150 per year, often covered by insurance or government programs.
• Specialized or Travel Vaccines: $150 - $1,000 depending on the number of vaccines and travel destination.
• Therapeutic Vaccines (Cancer, Chronic Infections): $5,000 - $50,000 or more for full treatment courses.
• Administration and Clinical Costs: $50 - $1,000 for administration and consultations, depending on the setting and number of doses required.​

7. Immunotherapy — Immunotherapy boosts the body’s natural defenses to fight infections. Some immunotherapies involve administering immune molecules like cytokines or interferons, while others stimulate the body’s immune cells directly. Immunotherapy is used in treating infections, particularly in immunocompromised individuals or those with chronic infections. It reduces reliance on antibiotics and strengthens the body's ability to fight infections.

Immunotherapy is already widely used for cancer and some viral infections (e.g., COVID-19). For bacterial infections, it's still in experimental stages, with a focus on boosting the body’s natural immune response to fight infections. Translating success from cancer treatment into infection control will take time, as bacterial immunotherapies are still in clinical trial phases. Estimated Availability is 5 to 10 years (for bacterial infections).

What will it cost?

• Cancer Immunotherapy: $100,000 - $400,000 per year, with CAR T-cell therapy and other advanced treatments potentially costing up to $475,000.
• Autoimmune Disease Immunotherapy: $30,000 - $70,000 per year for biologic drugs used to treat conditions like rheumatoid arthritis or Crohn’s disease.
• Allergy Immunotherapy: $1,000 - $3,000 per year, with total costs over the course of treatment ranging from $3,000 to $15,000.
• Administration and Monitoring: $1,500 - $5,000 per infusion, plus regular consultations and diagnostic tests adding $1,000 - $5,000 annually.​

8. Bacteriocins — Bacteriocins are antimicrobial peptides produced by certain bacteria that inhibit the growth of other bacteria (primarily similar or closely related bacterial strains). Bacteriocins can specifically target pathogenic bacteria, acting like natural antibiotics. They've been explored for use in food preservation and as potential treatments for gastrointestinal infections. They target specific bacteria without broad-spectrum effects, helping preserve a healthy microbiome.​

Bacteriocins are in early research phases for medical applications. They are already used in food preservation, but clinical use as antibiotic alternatives is still in development. Creating formulations that are safe, stable, and effective for medical use is a key challenge, along with large-scale production. Estimated Availability is 5 to 10 years.

What will it cost?

• Experimental or Early-Stage Use: $10,000 - $50,000 per course of treatment for clinical trial participation or early-access programs, where the costs may be partially subsidized or offset.
• Medication Costs (Commercial Availability): $5,000 - $20,000 for the medication alone, depending on the type and scale of production.
• Administration and Monitoring: $1,000 - $5,000 per administration session, with additional costs for regular consultations and monitoring.
• Chronic or Complex Cases: $20,000 - $100,000 or more for long-term or repeated treatments, including all associated medical costs.

9. Silver Nanoparticles — Silver nanoparticles have antimicrobial properties and have been researched for their ability to kill bacteria. They can disrupt bacterial cell membranes and inhibit cellular functions. Silver nanoparticles are used in wound dressings, coatings for medical devices, and other infection-prevention products. They have a broad antimicrobial spectrum and are less likely to lead to resistance compared to antibiotics.

Silver-based treatments (e.g., silver sulfadiazine for burns) are already in use. Silver nanoparticles are in research and clinical trials for broader antimicrobial applications, including wound care and medical devices. Concerns about toxicity, long-term safety, and potential bacterial resistance are significant barriers to more widespread use. Estimated Availability is 5 to 10 years.

What will it cost?

• Topical Applications (Wound Dressings or Creams): $100 - $1,000 per month, or $1,200 - $12,000 per year** depending on the frequency of use.
• Systemic or Infusion-Based Treatments: $10,000 - $50,000 per course of treatment (if and when these become commercially available).
• Wound Care Administration: $500 - $2,000 per month if wound care is managed in a clinical setting, leading to annual costs of $6,000 - $24,000.
• Chronic Wound Treatment Protocols: $5,000 - $30,000 per year for long-term or chronic conditions involving silver nanoparticle-based products and care.
• Diagnostic and Monitoring: $500 - $3,000 annually for diagnostic testing and follow-up care.

10. Monoclonal Antibodies — Monoclonal antibodies are laboratory-made molecules that can mimic the immune system's ability to fight infections. These antibodies bind to specific bacterial or viral proteins, neutralizing pathogens or marking them for destruction by the immune system. Monoclonal antibodies are being used to treat viral infections like COVID-19 and bacterial infections resistant to traditional antibiotics. They offer a targeted approach with fewer off-target effects compared with antibiotics.

Monoclonal antibodies are already available for treating viral infections (for example, COVID-19) and chronic diseases (for example, cancer, and autoimmune disorders). Their use in treating bacterial infections is being actively researched, with some clinical trials already underway. Development of bacterial-specific monoclonal antibodies and ensuring cost-effectiveness for widespread use are key hurdles. Estimated Availability is 3 to 5 years (for bacterial infections)

What will it cost?

• Cancer Treatment with Monoclonal Antibodies: $50,000 - $200,000 per year, including medication, administration, and monitoring.
• Autoimmune Disease Treatment: $20,000 - $70,000 per year for long-term therapy, including drug costs, administration, and follow-up care.
• Infectious Disease Treatment: $2,000 - $10,000 for a short course of treatment, depending on the drug and number of doses.
• Administration and Monitoring: $10,000 - $50,000 per year for infusion sessions and follow-up care, depending on the condition being treated and the frequency of administration.